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A Case of Fatal Intoxication from Metformin*
ABSTRACT: A case of fatal intoxication from metformin is presented. The decedent was an obese 58-year-old-woman with type II diabetes, in
whom severe lactic acidosis secondary to metformin accumulation was precipitated by acute renal failure. She had been on metformin 500 mg twice
a day. Postmortem blood was deproteinated with acetonitrile, washed with dichloromethane, and the resulting supernatant injected into high-perform-
ance liquid chromatography system. Separation was performed on a analytical 125 · 4 mm i.d. RP-8 column. The wavelength was set at 235 nm.
The mobile phase was acetonitrile (40%), sodium lauryl sulfate, and sodium dihydrogen phosphate adjusted to pH 5.1 (60%) at a flow rate of
1.0 mL ⁄min. The concentration of metformin in postmortem blood was 77.3 lg ⁄mL. The qualitative result was also confirmed by LC ⁄AP-
CI ⁄MS ⁄MS analysis.
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Metformin (1,1-dimethyl biguanide) is antihyperglycemic, not
hypoglycemic. It causes neither insulin release from the pancreas
nor hypoglycemia, even when taken in large doses. It has no signi-
ficant effects on the secretion of glucagon, cortisol, growth hor-
mone, or somatostatin. The main causes of reduced glucose levels
during metformin therapy appear to be the increased action of insu-
lin in peripheral tissues and reduced hepatic glucose output due to
inhibition of gluconeogenesis. Metformin may also decrease plasma
glucose by reducing the absorption of glucose from intestine, but
this action has not been shown to have clinical importance.
Patients with renal impairment should not receive metformin.
Liver disease, past history of lactic acidosis (of any cause) cardiac
failure, or chronic hypoxic lung disease also are contraindications
to the use of metformin. All these conditions predispose to
increased lactate production and hence to the fatal complications of
lactic acidosis. The reported incidence of lactic acidosis during met-
formin treatment is lower than 0.1 cases per 1000 patient-years,
and the mortality risk is even lower (1).
Case History
An obese woman, suffering from many pathologies—type II dia-
betes treated with insulin and oral hypoglycemic agents (Metbay
500 Bayer, containing 500 mg of metformin hydrochloride with
starch and talc as inactive ingredients), obstructive arteriopathy of the
lower limbs, arterial hypertension, previous myocardial infarct, and
grade II esophagitis—was taken to hospital due to the onset, about
4 days previously, of vomiting and fever, associated with dyspnea
with retrosternal pain, which were partially reduced after administra-
tion of nitroderivates (Carvasin s.l.). After ECG (loss of R wave
voltage in V1-V3) and laboratory tests (leukocytes 12.43 103lL;
hemoglobin 14.6 g ⁄dL; urea 1.43 g ⁄L; creatinine 9.0 mg ⁄dL; glu-
cose 2.76 g ⁄L; LDH 513 U ⁄L; Na 126 meq ⁄L; K 7.4 meq ⁄L; tropo-
nin 0.09 ng ⁄mL; lactic acid 103 mg ⁄dL), clinicians diagnosed acute
renal failure. The patient was hospitalized in the Nephrology Depart-
ment where, in view of her metabolic picture, urgent hemodialysis
was carried out and interrupted after 2 h. A following arterial hemo-
gasanalysis showed: pH of 7.013, K 6.00 meq ⁄L and HCO3)
7.10 mmol ⁄L; after only 45 min these values changed into: pH
7.013, K 6.09 meq ⁄L, HCO3) 5.2 mmol ⁄L. The patient was consid-
ered to be in critical condition. Another ECG was effectuated and
showed alterations attributed to a probable intermittent complete left
bundle-branch block; the hematological test results releaved a high
value of troponin (2.44 ng ⁄dL).
About 17 h after hospitalization, in spite of treatment received,
she died of ‘‘cardiogenic shock with lactic acidosis, in a patient
suffering from diabetes and postinfarct ischemic cardiopathy.’’
Autopsy and histological findings revealed that the death was due
to terminal cardiocirculatory arrest resulting from cardiogenic shock
after severe acidosis.
Materials and Methods
Reagents and Chemicals
All reagents were of analytical grade. Metformin was obtained
from Sigma–Aldrich (St. Louis, MO). Acetonitrile, dichloromethane,
sodium lauryl sulfate, and sodium dihydrogen phosphate were obtai-
ned from Merck (Darmastadt, Germany). Ultrapure water (18.2 MX)
used to prepare the mobile phase was obtained by double distillation
and further purified with a Milli-Q system (Millipore, Bedford, MA).
Instrumentation
Chromatographic experiments were performed on an HPLC sys-
tem consisting of an HP 1050 liquid chromatograph (Hewlett-Pack-
ard, Palo Alto, CA) equipped with a UV detector connected to a
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HPLC ChemStation. Separation was performed on a analytical
125 · 4 mm i.d. Lichrosphere RP-8 (5 lm particle size) column
coupled with a RP-18 guard column (5 lm particle size) (Merck).
The mobile phase was 40% solution A and 60% solution B was
pumped at a flow-rate of 1 mL ⁄min (107–109 bar). Solution A
was acetonitrile; solution B was prepared weighing 1.73 g of
sodium lauryl sulfate and 0.828 g of sodium dihydrogen phosphate
in 600 mL of water, adjusted to pH 5.1. This was then filtered
through a 0.45-lm Millipore filter and degassed ultrasonically
before used. The detector wavelength was set at 235 nm and peak
areas were measured. In this condition, metformin retention time
was 2.81 min at room temperature.
Standard Samples
Standard solution of metformin was prepared in mobile phase at
concentration of 75.9 lg ⁄mL. Three standard samples were pre-
pared by adding 200 lL of metformin standard solution to 800 lL
of drug-free blood to give a final concentration 15.2 lg ⁄mL. The
samples were extracted according to the described method. The
drug-free blood is constituted by 1 mL of blood from a subject
who had not died due to intake of drugs. Every sample was injec-
ted three times (CV% = 3.4).
Extraction of Postmortem Blood Sample
One milliliter of acetonitrile was added to 1 mL of postmortem
cardiac blood from the patient. After vortex mixing, the tube was
centrifuged at 3956 g for 15 min, and the transferred supernatant
was washed with dichloromethane by vortex-mixing for 30 sec.
After centrifugation, the aqueous layer was diluted 1:5 with mobile
phase and 10 lL of this solution injected into the HPLC ⁄UV
instrument.
Results
Because the case history indicated intoxication due to drugs not
routinely included in laboratory testing, the extraction method des-
cribed by Zarghi et al. and Cheng and Chou (2,3) was applied, duly
modified, to search for metformin in postmortem blood. Systematic
toxicological analysis (STA) was carried out on the sample, to
reveal the possible presence of illegal drugs, medicinal drugs, alco-
hol, volatile substance and ⁄or other poisons, but none was found.
Identification of metformin was based on the retention time (tR)
and on the HPLC ⁄UV analysis carried out on the postmortem
blood sample. The qualitative result was also confirmed by
LC ⁄APCI ⁄MS ⁄MS analysis (Figs. 1 and 2) in the chromatographic
conditions shown in Table 1. Quantitative analysis was carried out
in HPLC ⁄UV and the resulting concentration of metformin in the
postmortem blood was 77.3 lg ⁄mL.
Discussion and Conclusions
Type II diabetes mellitus—insulin resistance—is the most fre-
quent form of diabetes in Italy. Although not depending on the
supplies of exogenous insulin for their survival, patients with this
pathology may use insulin in order to correct hyperglycemia.
Most patients with type II diabetes are overweight: obesity is in
FIG. 1—(a) LC ⁄APCI ⁄MS ⁄MS chromatogram (m ⁄ z 50–150) of 1 mL extract of blank human blood spiked with 15.2 lg of metformin (tR = 3.40 min) and
(b) mass spectra of metformin.
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itself a cause of insulin resistance. Although several metabolic
complications may sometimes occur, e.g., hyperomolarity or keto-
acidosis, in patients with type II diabetes hyperglycemia does not
generally involve an immediate risk of death. However, chronic
hyperglycemia may lead to micro-angiopathic (retinopathy, kidney
disease) and macro-angiopathic complication (myocardial infarct,
obliterating arteriopathy of lower limbs) which, as in the case
reported here, may considerably influence both the length and the
quality of life of patients. Metformin, in the form of 500- and
850-mg tablets, is available in Italy. It is a member of the bigua-
nide family, the drugs which reduce glycemia in patients with
type II diabetes without stimulating insulin secretion. Biguanides
enhance the exploitation of glucose, both in the intestine and in
the skeletal muscle. Whereas in muscular tissue, aerobic glycolysis
prevails with complete oxidation of glucose and production of car-
bon dioxide, and in the intestine anaerobic glycolysis amply
prevails with the production of lactate. From the intestine, lactate
is transported by means of portal circulation to the liver, where it
is normally used for gluconeogenesis. Instead, when the portal
concentrations of lactate are very high, liver clearance may be
insufficient, causing increased quantities of lactate in the systemic
circulation. Lactic acidosis, which initially presents with aspecific
symptoms (gastro-enteric disturbances, muscle pain, cramps, asthe-
nia torpor) is a potentially serious event with high mortality. As
metformin is mainly excreted through the kidney, it may accumu-
late in cases of renal insufficiency. In our patient, as there was no
information on what therapy she had been following in the days
before her hospitalization, and data on renal and hepatic indexes
of functionality were not known, it was impossible to establish
whether the last dose of metformin was to be reduced or even
completely avoided, in order not to increase the risk of lactic
acidosis, with consequent involvement of kidney functions. There-
fore, it was impossible to establish whether the toxic state of the
patient, with high lactacidemia values was pre-existent, or whether
it had been triggered by her last dose of metformin. It could only
be stated that the metformin values found in blood were compar-
able with levels reported in the literature (4–7) in cases of lactic
acidosis due to accumulation of lactate as a consequence of
severe renal failure.
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TABLE 1—LC ⁄APCI ⁄MS ⁄MS chromatographic conditions.
Instrument Finnigan LCQTMDUO, equipped with APCI source
Pump Binary LC Pump 250 (Perkin Elmer)
Column Luna—CN 150 · 4.6 mm I.D., 3 lm (Phenomenex)
Mobile Phase 30% Ammonium acetate 0.01 M
70% Acetonitrile–methanol (1–1)
Flow 0.8 mL ⁄min
Source voltage 5.0 kV
Discharge current 4 lA
Capillary temperature 150C
Vaporizer temperature 450C
Collision energy For the fragmentation of molecular ion
130 m ⁄ z [M + H]+ at 27% of maximum value
FIG. 2—(a) LC ⁄APCI ⁄MS ⁄MS chromatogram (m ⁄ z 50–150) of postmortem blood sample and (b) mass spectra of metformin.
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